发明授权
US5562904A Retroviral transduction of cells using soluble complement inhibitors
失效
使用可溶性补体抑制剂逆转录病毒转导细胞
- 专利标题: Retroviral transduction of cells using soluble complement inhibitors
- 专利标题(中): 使用可溶性补体抑制剂逆转录病毒转导细胞
-
申请号: US278550申请日: 1994-07-21
-
公开(公告)号: US5562904A公开(公告)日: 1996-10-08
- 发明人: Russell P. Rother , Scott A. Rollins , James M. Mason , Stephen P. Squinto
- 申请人: Russell P. Rother , Scott A. Rollins , James M. Mason , Stephen P. Squinto
- 申请人地址: CT New Haven
- 专利权人: Alexion Pharmaceuticals, Inc.
- 当前专利权人: Alexion Pharmaceuticals, Inc.
- 当前专利权人地址: CT New Haven
- 主分类号: C12N15/09
- IPC分类号: C12N15/09 ; A61K38/00 ; A61K39/395 ; A61K45/00 ; A61K48/00 ; A61P43/00 ; C07K16/18 ; C12P21/08 ; B61K39/395
摘要:
Methods and compositions are provided for facilitating gene therapy procedures involving the transduction of target cells with retroviral vector particles in the presence of complement containing body fluids. The administration of soluble complement inhibitor molecules to body fluids prevents the complement mediated inactivation of the retroviral vector particles, and provides a safety mechanism for such gene therapy procedures, as the action of soluble complement inhibitors is transient, and any retroviral vector particles present after the return of uninhibited complement activity will be inactivated. Preferred soluble complement inhibitors for use in the practice of the present invention include complement inhibitory anti-complement component mAbs (including complement inhibitory anti C5 antibodies).
公开/授权文献
- US4912780A Combined shirt and religious garment 公开/授权日:1990-04-03